ANTI-CD73 ANTIBODY AND USE THEREOF
The present invention addresses the problem of developing an antibody which targets a CD73 antigen and has a higher function, more specifically, an antibody which is for treating cancer and has a higher activity. The present invention has shown that the problem can be solved by finding an antibody o...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French Japanese |
Published |
02.12.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention addresses the problem of developing an antibody which targets a CD73 antigen and has a higher function, more specifically, an antibody which is for treating cancer and has a higher activity. The present invention has shown that the problem can be solved by finding an antibody or a human antibody derivative which includes a heavy or light chain complementarity-determining region having a specific amino acid sequence, has binding properties to a CD73 antigen, and activates T cells having the property of damaging cancer cells.
La présente invention aborde le problème de développement d'un anticorps qui cible un antigène CD73 et a une fonction plus élevée, plus spécifiquement, un anticorps pour le traitement du cancer et ayant une activité plus élevée. La présente invention a démontré que le problème peut être résolu par la découverte d'un anticorps ou d'un dérivé d'anticorps humain qui comprend une région de détermination de complémentarité de chaîne lourde ou légère ayant une séquence d'acides aminés spécifique, a des propriétés de liaison à un antigène CD73, et active des lymphocytes T ayant la propriété de détériorer des cellules cancéreuses.
本発明は、CD73抗原を標的としたより高い機能を有する抗体、より具体的にはより高い活性を有するがん治療用抗体を開発することを課題とする。 本発明は、特定のアミノ酸配列を有する重鎖・軽鎖の相補性決定領域を含む、CD73抗原に対して結合性を有し、がん細胞に対する傷害性を有するT細胞を活性化する、抗体またはヒト型抗体誘導体を見出し、上記課題を解決することができることを示した。 |
---|---|
AbstractList | The present invention addresses the problem of developing an antibody which targets a CD73 antigen and has a higher function, more specifically, an antibody which is for treating cancer and has a higher activity. The present invention has shown that the problem can be solved by finding an antibody or a human antibody derivative which includes a heavy or light chain complementarity-determining region having a specific amino acid sequence, has binding properties to a CD73 antigen, and activates T cells having the property of damaging cancer cells.
La présente invention aborde le problème de développement d'un anticorps qui cible un antigène CD73 et a une fonction plus élevée, plus spécifiquement, un anticorps pour le traitement du cancer et ayant une activité plus élevée. La présente invention a démontré que le problème peut être résolu par la découverte d'un anticorps ou d'un dérivé d'anticorps humain qui comprend une région de détermination de complémentarité de chaîne lourde ou légère ayant une séquence d'acides aminés spécifique, a des propriétés de liaison à un antigène CD73, et active des lymphocytes T ayant la propriété de détériorer des cellules cancéreuses.
本発明は、CD73抗原を標的としたより高い機能を有する抗体、より具体的にはより高い活性を有するがん治療用抗体を開発することを課題とする。 本発明は、特定のアミノ酸配列を有する重鎖・軽鎖の相補性決定領域を含む、CD73抗原に対して結合性を有し、がん細胞に対する傷害性を有するT細胞を活性化する、抗体またはヒト型抗体誘導体を見出し、上記課題を解決することができることを示した。 |
Author | SASAKURA Yukie NOZAWA Risa MATSUMOTO Noriko BAN Haruka NAKAMURA Norihiro OBONAI Toshifumi MISHIMA Yuji |
Author_xml | – fullname: NOZAWA Risa – fullname: MISHIMA Yuji – fullname: NAKAMURA Norihiro – fullname: OBONAI Toshifumi – fullname: MATSUMOTO Noriko – fullname: BAN Haruka – fullname: SASAKURA Yukie |
BookMark | eNrjYmDJy89L5WRQcvQL8dR1djE3VgCxnPxdIoEMF4XQYFeFEA_XIFd_Nx4G1rTEnOJUXijNzaDs5hri7KGbWpAfn1pckJicmpdaEh_ub2RgZGhkYmhuZOloaEycKgBzJySk |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | ANTICORPS ANTI-CD73 ET SON UTILISATION 抗CD73抗体およびその用途 |
ExternalDocumentID | WO2021241729A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO2021241729A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 12:49:40 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French Japanese |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO2021241729A13 |
Notes | Application Number: WO2021JP20384 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211202&DB=EPODOC&CC=WO&NR=2021241729A1 |
ParticipantIDs | epo_espacenet_WO2021241729A1 |
PublicationCentury | 2000 |
PublicationDate | 20211202 |
PublicationDateYYYYMMDD | 2021-12-02 |
PublicationDate_xml | – month: 12 year: 2021 text: 20211202 day: 02 |
PublicationDecade | 2020 |
PublicationYear | 2021 |
RelatedCompanies | BRIGHTPATH BIOTHERAPEUTICS CO., LTD |
RelatedCompanies_xml | – name: BRIGHTPATH BIOTHERAPEUTICS CO., LTD |
Score | 3.481101 |
Snippet | The present invention addresses the problem of developing an antibody which targets a CD73 antigen and has a higher function, more specifically, an antibody... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
Title | ANTI-CD73 ANTIBODY AND USE THEREOF |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211202&DB=EPODOC&locale=&CC=WO&NR=2021241729A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTMCdtfMUk11LRKTzXRNksySdYHdICCRZmqRaJhskZIE3hTm62fmEWriFWEawcSQA9sLAz4ntBx8OCIwRyUD83sJuLwuQAxiuYDXVhbrJ2UChfLt3UJsXdSgvWNgbwZIqLk42boG-Lv4O6s5OwP7bWp-QWA5YGUFbEo6AvtKrKCGNOikfdcwJ9C-lALkSsVNkIEtAGheXokQA1NWojADpzPs7jVhBg5f6JQ3kAnNfcUiDEqOfiGeus4u5sYKIJaTv0skkOGiEBrsqhDi4Rrk6u8myqDs5hri7KELtCwe7rf4cH9klxmLMbAAe_2pEgwKicZpBmnA6tQkCVgBmySlJKWmJCalmBimAiudFANLA0kGGXwmSeGXlmbgAnHB6zKMZBhYSopKU2WBtWtJkhw4UADAUnj2 |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFetNq-KjalDJLZg2j8ZDkWY3IdUmW2qq7Slk8wBL0WIj_n0nS6o99bIMO7AvmP32252ZBbgzO0jXzMxQrDgxFZ2biYI0CIvcsOJ2YqVcBIX5gelN9KepMa3BYh0LI_KE_ojkiGhRCdp7Ifbr5f8lFhW-lat7_o5Vn49u2KNyxY6RzWAhU7vnjBhlRCYEeZscjIUOwQqPkn3kSjvdMj9veXh6tcu4lOUmqLgHsDvC9j6KQ6jN4yY0yPrvtSbs-dWTN4qV9a2O4KYfhAOF0K4mlZLN6AwFKk1eHCn0nLHD3GO4dZ2QeAp2Fv3NLXpjmyPTTqCOrD87BSnWcjVHONU5ArDOU56lMU_1doagk6oP6hm0trV0vl19DQ0v9IfRcBA8X8B-qRI-Gp0W1Iuv7-wSkbbgV2KBfgGQ0Hvj |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTI-CD73+ANTIBODY+AND+USE+THEREOF&rft.inventor=NOZAWA+Risa&rft.inventor=MISHIMA+Yuji&rft.inventor=NAKAMURA+Norihiro&rft.inventor=OBONAI+Toshifumi&rft.inventor=MATSUMOTO+Noriko&rft.inventor=BAN+Haruka&rft.inventor=SASAKURA+Yukie&rft.date=2021-12-02&rft.externalDBID=A1&rft.externalDocID=WO2021241729A1 |